Elo Mutual Pension Insurance Co Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Elo Mutual Pension Insurance Co decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,372 shares of the biopharmaceutical company’s stock after selling 95 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Alnylam Pharmaceuticals were worth $2,763,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Allspring Global Investments Holdings LLC boosted its stake in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in Alnylam Pharmaceuticals in the second quarter valued at about $26,000. Altitude Crest Partners Inc. purchased a new position in Alnylam Pharmaceuticals in the first quarter worth about $30,000. Robeco Institutional Asset Management B.V. grew its stake in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares during the period. Finally, V Square Quantitative Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $276.33 on Friday. The business’s 50 day simple moving average is $259.54 and its 200-day simple moving average is $197.32. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55. The stock has a market capitalization of $34.95 billion, a price-to-earnings ratio of -103.53 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same period in the previous year, the firm earned ($2.21) earnings per share. The company’s revenue was up 107.0% compared to the same quarter last year. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the transaction, the executive vice president now directly owns 14,181 shares in the company, valued at approximately $3,275,669.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the transaction, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The disclosure for this sale can be found here. Insiders have sold 103,148 shares of company stock worth $25,658,824 over the last quarter. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ALNY shares. Citigroup raised their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. TD Cowen boosted their price objective on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Stifel Nicolaus raised their target price on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. BMO Capital Markets reiterated an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday. Seven research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $279.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.